share_log

Kura Oncology Analyst Ratings

Kura Oncology Analyst Ratings

庫拉腫瘤分析師評級
Benzinga Analyst Ratings ·  2023/01/31 04:38
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/31/2023 89.83% Stifel → $25 Initiates Coverage On → Buy
07/13/2022 120.2% Credit Suisse $27 → $29 Maintains Outperform
07/12/2022 127.79% Cantor Fitzgerald → $30 Initiates Coverage On → Overweight
02/25/2022 105.01% Credit Suisse $25 → $27 Maintains Outperform
02/25/2022 112.6% SVB Leerink $41 → $28 Maintains Outperform
02/15/2022 165.76% Jefferies → $35 Initiates Coverage On → Buy
11/26/2021 59.45% Credit Suisse $40 → $21 Maintains Outperform
11/24/2021 142.98% HC Wainwright & Co. $43 → $32 Maintains Buy
08/06/2021 203.72% Credit Suisse $42 → $40 Maintains Outperform
08/06/2021 211.31% SVB Leerink $40 → $41 Maintains Outperform
02/26/2021 203.72% SVB Leerink $42 → $40 Maintains Outperform
02/24/2021 226.5% HC Wainwright & Co. $45 → $43 Maintains Buy
12/07/2020 241.69% HC Wainwright & Co. $40 → $45 Maintains Buy
12/03/2020 241.69% Stifel → $45 Initiates Coverage On → Buy
10/12/2020 203.72% HC Wainwright & Co. $22 → $40 Maintains Buy
10/08/2020 226.5% Credit Suisse $27 → $43 Maintains Outperform
07/07/2020 105.01% Credit Suisse → $27 Initiates Coverage On → Outperform
06/01/2020 105.01% Oppenheimer $23 → $27 Maintains Outperform
05/06/2020 112.6% Wedbush $30 → $28 Maintains Outperform
05/05/2020 74.64% Oppenheimer $27 → $23 Maintains Outperform
05/05/2020 67.05% HC Wainwright & Co. $29 → $22 Reiterates → Buy
05/05/2020 82.23% Barclays → $24 Initiates Coverage On → Overweight
09/05/2019 67.05% JMP Securities → $22 Reinstates → Market Outperform
07/18/2019 112.6% Deutsche Bank → $28 Initiates Coverage On → Buy
11/09/2018 89.83% Piper Sandler → $25 Initiates Coverage On → Overweight
08/01/2018 135.38% HC Wainwright & Co. → $31 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
01/31/2023 89.83% Stifel → $25 開始承保 →購買
07/13/2022 120.2% 瑞士信貸 $27 → $29 維護 跑贏大盤
07/12/2022 127.79% 康託·菲茨傑拉德 → $30 開始承保 →超重
02/25/2022 105.01% 瑞士信貸 $25 → $27 維護 跑贏大盤
02/25/2022 112.6% SVB Leerink $41 → $28 維護 跑贏大盤
02/15/2022 165.76% 傑富瑞 → $35 開始承保 →購買
11/26/2021 59.45% 瑞士信貸 $40 → $21 維護 跑贏大盤
11/24/2021 142.98% HC Wainwright公司 $43 → $32 維護 買
08/06/2021 203.72% 瑞士信貸 $42 → $40 維護 跑贏大盤
08/06/2021 211.31% SVB Leerink $40 → $41 維護 跑贏大盤
02/26/2021 203.72% SVB Leerink $42 → $40 維護 跑贏大盤
02/24/2021 226.5% HC Wainwright公司 $45 → $43 維護 買
12/07/2020 241.69% HC Wainwright公司 $40 → $45 維護 買
12/03/2020 241.69% Stifel → $45 開始承保 →購買
10/12/2020 203.72% HC Wainwright公司 $22 → $40 維護 買
10/08/2020 226.5% 瑞士信貸 $27 → $43 維護 跑贏大盤
07/07/2020 105.01% 瑞士信貸 → $27 開始承保 →跑贏大盤
06/01/2020 105.01% 奧本海默 $23 → $27 維護 跑贏大盤
05/06/2020 112.6% 韋德布什 $30 → $28 維護 跑贏大盤
05/05/2020 74.64% 奧本海默 $27 → $23 維護 跑贏大盤
05/05/2020 67.05% HC Wainwright公司 $29 → $22 重申 →購買
05/05/2020 82.23% 巴克萊 → $24 開始承保 →超重
09/05/2019 67.05% JMP證券 → $22 恢復 →市場跑贏大盤
07/18/2019 112.6% 德意志銀行 → $28 開始承保 →購買
11/09/2018 89.83% 派珀·桑德勒 → $25 開始承保 →超重
08/01/2018 135.38% HC Wainwright公司 → $31 開始承保 →購買

What is the target price for Kura Oncology (KURA)?

庫拉腫瘤(Kura)的目標價是多少？

The latest price target for Kura Oncology (NASDAQ: KURA) was reported by Stifel on January 31, 2023. The analyst firm set a price target for $25.00 expecting KURA to rise to within 12 months (a possible 89.83% upside). 6 analyst firms have reported ratings in the last year.

Stifel於2023年1月31日報道了庫拉腫瘤學(納斯達克：KURA)的最新目標價。這家分析公司將目標價定為25.00美元，預計Kura將在12個月內上漲(可能上漲89.83%)。6家分析公司在過去一年公佈了評級。

What is the most recent analyst rating for Kura Oncology (KURA)?

庫拉腫瘤學(Kura)的最新分析師評級是多少？

The latest analyst rating for Kura Oncology (NASDAQ: KURA) was provided by Stifel, and Kura Oncology initiated their buy rating.

Stifel提供了對Kura Oncology(納斯達克：KURA)的最新分析師評級，Kura Oncology啟動了他們的買入評級。

When is the next analyst rating going to be posted or updated for Kura Oncology (KURA)?

Kura Oncology(Kura)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kura Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kura Oncology was filed on January 31, 2023 so you should expect the next rating to be made available sometime around January 31, 2024.

分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與Kura Oncology的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Kura Oncology的上一次評級是在2023年1月31日提交的，所以你應該預計下一次評級將在2024年1月31日左右的某個時候提供。

Is the Analyst Rating Kura Oncology (KURA) correct?

分析師對Kura Oncology(Kura)的評級正確嗎？

While ratings are subjective and will change, the latest Kura Oncology (KURA) rating was a initiated with a price target of $0.00 to $25.00. The current price Kura Oncology (KURA) is trading at is $13.17, which is within the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的Kura腫瘤學(Kura)評級是以0.00美元至25.00美元的目標價啟動的。Kura Oncology(Kura)目前的交易價格為13.17美元，在分析師的預測範圍內。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論